Philippe Subrin - STAAR Surgical Vice President - Switzerland Operations

STAA Stock  USD 17.50  0.19  1.07%   

President

Mr. Philippe Subrin serves as Vice President, Collamer Lens Manufacturing and General Manager, Nidau Operations of STAAR Surgical Company. Mr. Subrin joined STAAR Surgical AG, our subsidiary in Nidau, Switzerland in January 2002 and served as Vice President, Switzerland Operations. He moved to the Monrovia facility in July 2014 and is responsible for ICL Manufacturing. Previously, he has held senior manufacturing positions at Bausch Lomb, one of the largest surgical ophthalmic companies, and Domilens in France. In 1995, he was Manufacturing Manager at Bausch Lomb in Lyons, France and responsible for the companys intraocular lens manufacturing line. While working at Bausch Lomb in Florida, Philippe focused on process improvements and development for their 3 piece silicone IOL. Mr. Subrin earned a degree in Optometry from the University of Morez in France and also a degree in Engineering and Operational Management from the University of Lyon in Lyon, France. since 2017.
Age 60
Tenure 8 years
Address 25510 Commercentre Drive, Lake Forest, CA, United States, 92630
Phone626 303 7902
Webhttps://www.staar.com

STAAR Surgical Management Efficiency

The company has return on total asset (ROA) of (0.0155) % which means that it has lost $0.0155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0516) %, meaning that it created substantial loss on money invested by shareholders. STAAR Surgical's management efficiency ratios could be used to measure how well STAAR Surgical manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.08. The current year's Return On Capital Employed is expected to grow to 0.12. At present, STAAR Surgical's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 148.7 M, whereas Intangible Assets are forecasted to decline to about 147.9 K.
STAAR Surgical currently holds 38.74 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. STAAR Surgical has a current ratio of 6.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about STAAR Surgical's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Marc PrieurAptarGroup
58
George MillerWest Pharmaceutical Services
64
Stewart StrongHaemonetics
58
James LimBecton Dickinson and
56
Betty LarsonBecton Dickinson and
44
Kim SeaburyAngioDynamics
58
Roy GalvinHaemonetics
54
Bobby GhoshalResMed Inc
52
Eldon SchafferAptarGroup
53
Virginia SanzoneICU Medical
50
Michelle BasilHaemonetics
52
Jeffrey KapplerEnvista Holdings Corp
41
Christopher DelOreficeBecton Dickinson and
53
Alexandre ConroyBecton Dickinson and
57
Chad CampbellAngioDynamics
54
Xiangwei GongAptarGroup
54
Holly SheffieldThe Cooper Companies,
54
David HelselAngioDynamics
60
Daniel McBrideThe Cooper Companies,
56
Roland GoetteBecton Dickinson and
58
Jan VerstrekenHologic
57
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Staar Surgical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 692 people. STAAR Surgical (STAA) is traded on NASDAQ Exchange in USA. It is located in 25510 Commercentre Drive, Lake Forest, CA, United States, 92630 and employs 1,157 people. STAAR Surgical is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

STAAR Surgical Leadership Team

Elected by the shareholders, the STAAR Surgical's board of directors comprises two types of representatives: STAAR Surgical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STAAR. The board's role is to monitor STAAR Surgical's management team and ensure that shareholders' interests are well served. STAAR Surgical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STAAR Surgical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Nancy Sabin, Chief Officer
Brian Moore, IR Contact Officer
Warren Foust, Chief Officer
HansMartin Blickensdoerfer, President International Commercial Operations
Thomas Frinzi, CEO President
Samuel Gesten, Vice President General Counsel, Corporate Compliance Officer and Secretary
Caren Mason, CEO and President Director and Chairman of Quality and Regulatory Committee
Joanne Egamino, Global Operations
Patrick Williams, Chief Officer
Robert Studholme, Senior Operations
Stephen CFA, CEO President
James Francese, VP of Global Marketing
Keith Holliday, Vice President - Research & Development
Scott MD, Chief Officer
Nathaniel Esq, General Secretary
Magda Michna, Regulatory Clinical
Philippe Subrin, Vice President - Switzerland Operations

STAAR Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is STAAR Surgical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether STAAR Surgical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of STAAR Surgical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Staar Surgical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Staar Surgical Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in STAAR Surgical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade STAAR Stock refer to our How to Trade STAAR Stock guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of STAAR Surgical. If investors know STAAR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about STAAR Surgical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.018
Earnings Share
(0.41)
Revenue Per Share
6.39
Quarterly Revenue Growth
(0.36)
Return On Assets
(0.02)
The market value of STAAR Surgical is measured differently than its book value, which is the value of STAAR that is recorded on the company's balance sheet. Investors also form their own opinion of STAAR Surgical's value that differs from its market value or its book value, called intrinsic value, which is STAAR Surgical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because STAAR Surgical's market value can be influenced by many factors that don't directly affect STAAR Surgical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between STAAR Surgical's value and its price as these two are different measures arrived at by different means. Investors typically determine if STAAR Surgical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, STAAR Surgical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.